Company: PTPI
Filing Date: 2025-01-24
Form Type: S-1
Source: 0001410578-25-000047
Chunk: 211

Company: Petros Pharmaceuticals, Inc.
Filing Date: 2025-01-24
Form: S-1
Chunk 211
---
 |   996,637 |
| Thereafter |   | ​ |   765,091 |
| Total      | ​ | $ | 8,971,737 |

The intangible assets held by the Company are the Stendra® product, Timm Medical product, and PTV product and are being amortized over their estimated useful lives of , , and , respectively. The carrying value of the Stendra® product, Timm Medical product, and PTV product as of December 31, 2023, are $ million, $ million and $ million, respectively. The carrying value of the Stendra® product, Timm Medical product, and PTV product as of December 31, 2022, are $ million, $ million and $ million, respectively. During the year ended December 31, 2023, impairment was recorded. During the year ended December

F-17

31, 2022, the Company determined that the intangible asset related to the Stendra® product was impaired resulting in an impairment charge of approximately $ 7.5million.

7) Accrued Expenses

Accrued expenses are comprised of the following:

| ​                         | ​ 
 ​ | ​ |                 ​ 
 December 31, 2023 | ​ | ​ |                 ​ 
 December 31, 2022 |
|:--------------------------|:--|:--|------------------:|:--|:--|------------------:|
| Accrued product returns   | ​ | $ |         4,178,176 | ​ | $ |         2,311,647 |
| Accrued contract rebates  | ​ |   |           128,562 | ​ |   |           279,018 |
| Due to 3PL/Wholesalers    | ​ |   |            75,727 | ​ |   |           155,081 |
| Accrued bonuses           | ​ |   |           665,184 | ​ |   |           427,500 |
| Accrued professional fees | ​ |   |            15,000 | ​ |   |            51,620 |
| Other accrued expenses    | ​ |   |           297,428 | ​ |   |           409,796 |
| Total accrued expenses    | ​ | $ |         5,360,077 | ​ | $ |         3,634,662 |

8) Debt

Promissory Note